CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06361888
Title field or adapter rule: {'original_value': 'A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:25.528726+00:00
Published At: 2026-09-17T00:00:00+00:00
Record Updated At: 2026-09-17
Source Retrieved At: 2026-10-31T22:17:56.788771+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Metastatic Pancreatic Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-17", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06361888"
protocolSection.identificationModule.officialTitle: "A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine'], 'description': 'Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine\n\n1. Surufatinib: 200mg, qd\n2. Camrelizumab: 200mg, IV drip, Q3W, D1\n3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8\n4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8', 'name': 'Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Nab-paclitaxel Plus Gemcitabine'], 'description': 'Drug: Nab-paclitaxel Plus Gemcitabine\n\n1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8\n2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8', 'name': 'Nab-paclitaxel Plus Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Surufatinib with Nab-paclitaxel, and Gemcitabine'], 'description': 'Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine\n\n1. Surufatinib: 200mg, qd\n2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8\n3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8', 'name': 'Surufatinib with Nab-paclitaxel, and Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.